Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.

摘要: Melanoma is a highly lethal cutaneous tumor, killing affected patients through development of multiple poorly immunogenic metastases. Suboptimal activation immune system by melanoma cells often due to molecular modifications occurring during tumor progression that prevent efficient recognition effectors. Statins are HMG-CoA reductase inhibitors, which block the mevalonate synthesis pathway, used millions people as hypocholesterolemic agents in cardiovascular and cerebrovascular diseases. They also known inhibit Rho GTPase dependent signaling pathways. GTPases regarded switches regulate wide spectrum cellular functions their dysfunction has been characterized various oncogenic process notably progression. Moreover, these molecules can modulate response. Since 10 years we have demonstrated other inhibitors critical regulators involved adaptive innate anti-melanoma In this review summarize our major observations demonstrating pharmacological stimulate immunogenicity suggest potential use promote